Treatment With Tiotropium Plus Olodaterol Respimat Improves Physical Functioning Of COPD Patients In A Real Life Setting

被引：0
|
作者：
Haensel, M. [1 ]
Glaab, T. [1 ]
Sauer, R. [2 ]
Rubin, R.
Buhl, R. [3 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[2] Lung Ctr Ulm, Ulm, Germany
[3] Mainz Univ Hosp, Mainz, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6810
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Lung-Function Response To Tiotropium plus Olodaterol In Patients With COPD With β-Agonist Reversibility
    Tashkin, D. P.
    Ferguson, G. T.
    Clerisme-Beaty, E.
    Vob, F.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [22] A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients
    Bateman, E. D.
    Tashkin, D.
    Siafakas, N.
    Dahl, R.
    Towse, L.
    Massey, D.
    Pavia, D.
    Zhong, N. S.
    RESPIRATORY MEDICINE, 2010, 104 (10) : 1460 - 1472
  • [23] Characteristics of Patients With and Without COPD Exacerbations During the Tiotropium plus Olodaterol TONADO Studies
    Abrahams, Roger
    Bjermer, Leif
    Ferguson, Gary
    Pizzichini, Emilio
    Voss, Florian
    Tafur, Carlos
    Buhl, Roland
    CHEST, 2016, 150 (04) : 858A - 858A
  • [24] Long-Term Safety Of Tiotropium/olodaterol Respimat® In Elderly Patients With Moderate To Very Severe COPD In The Tonado® Studies
    Ferguson, G. T.
    Maltais, F.
    Karpel, J.
    Bothner, U.
    Loaiza, L.
    Trampisch, M.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] Effects of tiotropium plus olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
    Singh, Dave
    Gaga, Mina
    Schmidt, Olaf
    Bjermer, Leif
    Groenke, Lars
    Voss, Florian
    Ferguson, Gary T.
    RESPIRATORY RESEARCH, 2016, 17
  • [26] Benefits Of Tiotropium plus Olodaterol Over Tiotropium At Delaying Clinically Significant Events In Patients With COPD Classified As Gold B
    Buhl, R.
    McGarvey, L.
    Korn, S.
    Ferguson, G. T.
    Gronke, L.
    Hallmann, C.
    Vob, F.
    Rabe, K. F.
    Maltais, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [27] Efficacy and safety of tiotropium plus olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
    Ferguson, Gary T.
    Karpel, Jill P.
    Clerisme-Beaty, Emmanuelle
    Groenke, L. Ars
    Voss, Florian
    Buhl, Roland
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2701 - 2710
  • [28] Long-Term Safety Of Tiotropium/olodaterol Respimat® In Patients With Moderate To Very Severe COPD And Renal Impairment In The Tonado® Studies
    LaForce, C.
    Derom, E.
    Bothner, U.
    Loaiza, L.
    Trampisch, M.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [29] Treatment with Olodaterol Respimat und Tiotropium HandiHaler shows additional Improvement of Lung Function in COPD in Comparison to Tiotropium: Results of two randomised, double-blind Studies
    Storre, J.
    Zuwallack, R.
    Allen, L.
    Hernandez, G.
    Ting, N.
    Abrahams, R.
    INTERNIST, 2015, 56 : 48 - 48
  • [30] LUNG FUNCTION WITH TIOTROPIUM PLUS OLODATEROL IN EAST ASIAN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Buhl, Roland
    Joens, Olaf
    Zhao, Yihua
    Ichinose, Masakazu
    RESPIROLOGY, 2015, 20 : 51 - 51
12345